IMSTA Joins Eucomed

medtech-europe

IMSTA joins Eucomed

Eucomed is an organisation advocating for the interests of the medical device industry in Europe. It represents directly and indirectly 4,500 designers, manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and management of disease and disability.  Eucomed represents a total of 11,000 legal entities in Europe.  It is part of MedTech Europe, an alliance with EDMA, the European Diagnostics Manufacturers Association.

Among its members, there are 24 national medical technology associations and 62 medical technology companies, comprising approximately 70% of the European market.  Eucomed has over 65 expert groups. These groups deal with regulatory, economic, public affairs, international and legal affairs topics.  Eucomed represents several sectors within medical technology such as ophthalmology, cardiovascular medicine, orthopaedics, advanced wound care and Community Care.

Eucomed’s main mission is to advocate for the medical device industry at the European level.  It engages with policymakers in European institutions and EU member states, patient groups, and medical associations.  Eucomed regularly organises meetings and workshops for members and stakeholders.  It lobbied extensively for the interests of the European medical device industry in the revision of the European medical device directive and advised IMSTA and IMDA in this regard.

IMSTA has been in touch with Eucomed since 2010, developing relationships with key personnel who have shared information on key trends and emerging position papers.  John Brennan, Director of Technical & Regulatory Affairs, has been a good supporter of IMSTA.  Prior to joining Eucomed John spent five years at the European Commission, having previously worked in and managed the Irish Notified Body, NSAI, where he gained extensive European and international experience in the design approval of high-risk medical devices and quality management systems.

IMSTA did not join Eucomed before now as the cost of membership was prohibitive relative to its’ value to IMSTA. We did however adopt Eucomed’s Code of Ethical Business Practice in 2011 and made it mandatory in 2013.

IMSTA’s CEO will spend the next 18 months engaging with Eucomed’s expert groups with a view to identifying how they can support the work of IMSTA nationally.  It may be possible for Chairpersons of IMSTA’s working groups to engage with and participate in appropriate expert groups such as the Procurement Working Group or on Reimbursement.  We intend to take full advantage of our membership and pass on the benefits of membership to our members.